MedTrace Logo

CD19-targeting CAR T Cells for B Cell Lymphoma

NCT02547948 · Status: WITHDRAWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL

Last updated 2020-07-16

No results posted yet for this study

Summary

The purpose of this study is to evaluate the safety and efficacy of CD19-targeting CAR T Cells infusion for B Cell Lymphoma.

Conditions

  • B Cell Lymphoma

Interventions

BIOLOGICAL

CD19-targeting CAR T Cells infusion

CD19-targeting 2nd generation CAR t cells infusion for refractory B cell lymphoma

Sponsors & Collaborators

  • Fuda Cancer Hospital, Guangzhou

    lead OTHER

Principal Investigators

  • Lizhi Niu, PhD · Fuda Cancer Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-09-30
Primary Completion
2016-08-15
Completion
2016-08-15

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02547948 on ClinicalTrials.gov